Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dongwha Pharm.Co.,Ltd (000020.KS)
Seoul, KR
Dongwha Pharm Co., Ltd. is a South Korean entity primarily engaged in the production and distribution of pharmaceutical goods. The company's diverse offerings include prescription-only medications addressing a wide spectrum of health concerns such as digestive and infectious diseases, cardiovascular and metabolic disorders, inflammatory and respiratory conditions, musculoskeletal and neurological ailments, as well as dermatological and urological issues. Furthermore, they market an extensive selection of over-the-counter (OTC) remedies, covering categories like digestive aids, cold and flu treatments, anti-inflammatory and respiratory solutions, skin care, oral hygiene, liver support, nutritional supplements, tonics, topical pain relief, antihistamines, and remedies for sore throats, among other products. Beyond pharmaceuticals, Dongwha Pharm also ventures into quasi-drugs, health supplements, food and beverage items, and cosmetics. Established in 1897, the firm maintains its headquarters in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.93% | -5.85% | -7.55% | -10.63% | -10.21% | -9.34% | -13.12% | -41.96% | -61.57% | -45.87% | +81.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.8% Q1'26: -48.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+56.1% ★ Q1'26: +29,050.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-4.2% Q1'26: -2.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-0.2% Q1'26: +8.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-0.1% Q1'26: +8.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.8% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.60× Q1'26: 1.83× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|
| Revenue |
272.08B
est: 273.00B (-0.3%)
|
293.02B
est: 277.00B (+5.8%)
|
340.43B
est: 280.00B (+21.6%)
|
361.11B
est: 382.50B (-5.6%)
|
464.87B
est: 407.30B (+14.1%)
|
496.39B
est: 437.00B (+13.6%)
|
| EBITDA |
44.75B
est: 33.20B (+34.8%)
|
39.41B
est: 33.69B (+17.0%)
|
38.23B
est: 34.05B (+12.3%)
|
48.74B
est: 46.52B (+4.8%)
|
28.72B
est: 39.61B (-27.5%)
|
21.16B
est: 42.49B (-50.2%)
|
| EBIT |
34.04B
est: 22.38B (+52.1%)
|
27.32B
est: 22.71B (+20.3%)
|
25.72B
est: 22.95B (+12.1%)
|
34.84B
est: 31.36B (+11.1%)
|
9.05B
est: 23.06B (-60.7%)
|
-809.25M
est: 24.75B (-103.3%)
|
| Net Income |
28.51B
est: 17.30B (+64.8%)
|
17.87B
est: 19.01B (-6.0%)
|
20.38B
est: 21.79B (-6.4%)
|
27.44B
est: 37.61B (-27.1%)
|
5.56B
est: 36.56B (-84.8%)
|
8.69B
est: 38.82B (-77.6%)
|
| SGA |
50.83B
est: 66.99B (-24.1%)
|
56.41B
est: 67.97B (-17.0%)
|
76.62B
est: 68.71B (+11.5%)
|
143.57B
est: 93.86B (+53.0%)
|
104.57B
est: 102.49B (+2.0%)
|
108.21B
est: 109.96B (-1.6%)
|
| EPS |
1,032.60
est: 624.00 (+65.5%)
|
646.68
est: 686.00 (-5.7%)
|
736.42
est: 786.00 (-6.3%)
|
991.07
est: 1,357.00 (-27.0%)
|
200.71
est: 1,309.00 (-84.7%)
|
313.37
est: 1,390.00 (-77.5%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 2/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 2/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 2/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 2/5 | 3/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.00% | 32.0K | 0.15% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 24.8K | 0.46% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 72.3K | 0.39% |
| 4 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 240.49 | 0.56% |
| 5 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 15.1K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Doh Joon Yoon | Chairman of the Board & Co-CEO | 1B | male |
| Chang-Soo Cho | Co-CEO & President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000020.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
